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Abstract
Background: The epigenetic clock, in particular epigenetic pre-aging quantified by the so-called DNA methylation
age acceleration, has recently been suggested to closely correlate with a variety of disease phenotypes. There
remains a dearth of data, however, on its association with telomere length and frailty, which can be considered
major correlates of age on the genomic and clinical level, respectively.
Results: In this cross-sectional observational study on altogether 1820 subjects from two subsets (n = 969 and
n = 851; mean ± standard deviation age 62.1 ± 6.5 and 63.0 ± 6.7 years, respectively) of the ESTHER cohort study of
the elderly general population in Germany, DNA methylation age was calculated based on a 353 loci predictor
previously developed in a large meta-study, and the difference-based epigenetic age acceleration was calculated as
predicted methylation age minus chronological age. No correlation of epigenetic age acceleration with telomere
length was found in our study (p = 0.63). However, there was an association of DNA methylation age acceleration
with a comprehensive frailty measure, such that the accumulated deficits significantly increased with increasing age
acceleration. Quantitatively, about half an additional deficit was added per 6 years of methylation age acceleration
(p = 0.0004). This association was independent from age, sex, and estimated leukocyte distribution, as well as from a
variety of other confounding variables considered.
Conclusions: The results of the present study suggest that epigenetic age acceleration is correlated with clinically
relevant aging-related phenotypes through pathways unrelated to cellular senescence as assessed by telomere
length. Innovative approaches like Mendelian randomization will be needed to elucidate whether epigenetic age
acceleration indeed plays a causal role for the development of clinical phenotypes.
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Background
DNA methylation patterns are known to change with
chronological age, and multiple CpG sites with replicable
associations with age have been identified [1]. Based on
regression coefficients estimated from a large number of
datasets, an individual’s chronological age can be pre-
dicted from DNA methylation data with high accuracy
[2]. The difference between the thus predicted methyla-
tion age (DNAm age) and the chronological age has
been termed “age acceleration” and, intriguingly, has
been found to be a substantially heritable trait in twin
study datasets that furthermore shows plausible associ-
ations with several phenotypes across studies and
tissues [2].
Frailty describes a clinical syndrome characterized by a
depletion of physical and cognitive resilience and re-
serves, commonly associated with an accumulation of
functional deficits [3, 4]. Frailty has received growing at-
tention in recent years, due to pronounced associations
with longevity and other aging-related phenotypes and
the corresponding perception that frailty measures
reflect an individual’s clinically relevant biological age
[4, 5]. Stable intra-individual differences in biological
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tion patterns might play a role in this phenomenon [7].
Telomere length (TL) has been suggested to reflect an
individual’s biological age at the genomic DNA level,
and associations of measures of TL with various aging-
and frailty-related phenotypes, such as sarcopenia [8]
and bone loss [9], have been reported. Whereas epigen-
etic age acceleration has been shown to be associated
with various cancer phenotypes [2], its correlation with
TL apparently has not been investigated to date, and
seemingly only one study has addressed age acceleration
and frailty [10]. In a rare study analyzing both TL and
DNAm age, the development of symptoms of post-
traumatic stress syndrome was associated with both var-
iables—in plausibly opposite, yet altogether unexpected
directions—but their mutual correlation apparently was
not investigated [11].
A better understanding of the interplay of epigenetic
and genomic correlates of age as determinants of clinical
frailty could help to elucidate novel pathways to healthy
aging and longevity. In the present study, the correlation
of epigenetic age acceleration with TL and frailty was in-
vestigated in two large subsets of a general population
sample of community-dwelling older adults in Germany.Table 1 Description of two subsets of the ESTHER study, an epidem
Characteristic
Total n
Age in years μ (SD)
Methylation age in years μ (SD)
Age acceleration in yearsb μ (SD)
Relative telomere length μ (SD)










<20 g/d (women), <40 g/d (men) n (%)
20+ g/d (women), 40+ g/d (men) n (%)
History of cancerc
Self-report negative n (%)
Self-report positive n (%)
Dataset 1, consecutively recruited subsample of the source study. Dataset 2, sample
a Chi-square test for categorical variables, t test for continuous variables
b Difference-based age acceleration, i.e., methylation age—chronological age
c Missing values (dataset 1, dataset 2) in smoking (20, 27), alcohol consumption (75In light of inconclusive previous findings on associations
of TL with frailty [12], interaction analyses were con-
ducted to evaluate whether DNAm age alters the associ-
ation of TL with frailty.
Results
Description of study population and main variables
Major characteristics of the study populations are shown
in Table 1. The two ESTHER subsets analyzed in the
present work—dataset 1 consisting of 1000 consecutively
recruited participants of the ESTHER cohort and dataset
2 originating from a case-cohort design (see “Methods”
section for details)—resembled one another closely, al-
though some of the slight differences between these two
very large subsets were statistically significant. The mean
age was 62.1 and 63.0 years, respectively. Methylation
age and difference-based epigenetic age acceleration ap-
peared somewhat higher in dataset 2, in which relative
telomere length also tended to be lower. There was no
difference with respect to the frailty index. Current
smoking was prevalent in one fifth of participants in
both datasets, and harmful alcohol consumption was re-
ported by less than 10 % of participants. Histograms of
the main analysis variables are shown in Additional fileiological study of the elderly general population in Germany
Dataset 1 Dataset 2 pa
969 851
62.1 (6.5) 63.0 (6.7) 0.0078
61.7 (7.1) 64.6 (7.7) <0.0001
−0.5 (5.0) 1.6 (5.3) <0.0001
1.22 (0.31) 1.03 (0.27) <0.0001
25.0 (14.7) 25.5 (15.1) 0.41
484 (50.0) 464 (54.5) 0.051
485 (50.1) 387 (45.5)
455 (48.0) 371 (45.0) 0.38
320 (33.7) 284 (34.5)
174 (18.3) 169 (20.5)
300 (33.6) 260 (33.7) 0.76
524 (58.6) 458 (59.4)
70 (7.8) 53 (6.9)
882 (93.2) 742 (90.5) 0.034
64 (6.8) 78 (9.5)
d in the context of a case-cohort study. For details, see text
, 80), and history of cancer (23, 31)
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whereas DNAm age acceleration and relative telomere
length closely followed a normal distribution.
Age acceleration and telomere length
When exploring the sex-adjusted associations of chrono-
logical age and methylation age with relative telomere
length in regression models of our combined dataset,
the associations of both variables with relative telomere
length were clearly significant (p < 0.0001; details not
shown). The corresponding F values were 46.8 for
chronological age and 32.9 for DNA methylation age,
suggesting a possibly closer correlation with cellular sen-
escence for the former variable. The results of regression
analyses of relative telomere length on difference-based
methylation age acceleration are shown in Table 2. In
both ESTHER subsets and in the combined analysis, the
estimated coefficients were small and not statistically
significant. The results of inverse sampling probability-
weighted regression (i.e., adjusting for the case-cohort
nature of substudy 2; see the “Methods” section) were
overall similar to the main analyses. For example, the es-
timate in the age-, sex- and leukocyte distribution-
adjusted model was −0.0004 instead of −0.0006, and the
result in the model additionally adjusted for cancer his-
tory was similarly stable and likewise changed to -0.0004
instead of −0.0006 (details not shown). Note that these
and all other regression models in the present work in-
cluded a random effect for the methylation array in
order to remove potential confounding by batch effects.
Age acceleration and frailty
The regression modeling of the frailty index on epigen-
etic age acceleration is summarized in Table 3. The
estimates suggested positive associations between ageTable 2 Results of linear mixed regression models predicting relativ
acceleration
Covariables Dataset 1
None 0.0013 (−0.0017, 0.0043)
Age −0.0009 (−0.0039, 0.0022)
Age, sex −0.0004 (−0.0035, 0.0027)
Age, sex, leucocyte distribution (LD) 0.0001 (−0.0033, 0.0034)
Age, sex, LD, smoking 0.0001 (−0.0033, 0.0035)
Age, sex, LD, alcohol −0.0002 (−0.0036, 0.0033)
Age, sex, LD, history of cancer 0.0001 (−0.0032, 0.0035)
Age, sex, LD, interaction (age accel. with sex)
Estimate in females −0.0020 (−0.0064, 0.0023)
Estimate in males 0.0024 (−0.0022, 0.0070)
Shown is the estimated change (95 % confidence interval) in RTL per year of age ac
assay batch using a random effect
ap values refer to type 3 tests of fixed effects of the overall modelacceleration and frailty index (FI) in both datasets, with
statistically significant results in the fully adjusted
models in both individual datasets and the combined
analysis. After adjustment for age, sex, and leukocyte
distribution, FI increased by about 0.25 % points per
year of epigenetic age acceleration.
To improve the interpretability of this result, we aimed
to derive a more tangible presentation of the estimated
association. Since the FI used increases by about 2.9 %
points per deficit, a 0.25 % points increase per year of
epigenetic age acceleration translates into one additional
deficit per 2.9/0.25 = 11.6 years of acceleration. Rounding
conservatively, we thus may state that our results sug-
gest one added deficit per 12 years of methylation age
acceleration, or half an added deficit per 6 years of
methylation age acceleration.
The adjustment for additional variables had no rele-
vant impact, and the results were comparable when ana-
lyzing women and men separately. In the latter analysis,
the confidence intervals around the male estimate in
dataset 1 and around the female estimate in dataset 2 in-
cluded the null effect, which might be due to sample size
limitations. Weighted regression likewise produced simi-
lar results (details not shown).
Interaction analysis of methylation and telomeres on
frailty
In the context of predicting frailty from relative telomere
length, the additional consideration of an interaction
with epigenetic age acceleration did not improve the
prediction of FI (Table 4), which renders it unlikely that
differences in epigenetic age acceleration could be re-
sponsible for the inconsistency of findings on associa-
tions between FI and telomere length in previous studies
(see the “Discussion” section below).e telomere length (RTL) from difference-based methylation age
Dataset 2 Overall pa
−0.0016 (−0.0044, 0.0012) 0.0000 (−0.0021, 0.0021) 1.00
−0.0031 (−0.0060,−0.0003) −0.0018 (−0.0039, 0.0003) 0.094
−0.0021 (−0.0050, 0.0007) −0.0011 (−0.0032, 0.0010) 0.30
−0.0014 (−0.0044, 0.0016) −0.0006 (−0.0028, 0.0017) 0.63
−0.0015 (−0.0046, 0.0015) −0.0006 (−0.0028, 0.0017) 0.63
−0.0017 (−0.0048, 0.0015) −0.0009 (−0.0032, 0.0015) 0.48
−0.0017 (−0.0047, 0.0013) −0.0006 (−0.0029, 0.0016) 0.58
−0.0014 (−0.0054, 0.0026) −0.0011 (−0.0041, 0.0018) 0.45
−0.0014 (−0.0056, 0.0028) 0.0001 (−0.0030, 0.0032) 0.96
celeration. All models are adjusted for methylation array batch and telomere
Table 3 Results of linear mixed regression models predicting the frailty index (FI) from difference-based methylation age
acceleration
Covariables Dataset 1 Dataset 2 Overall pa
None −0.023 (−0.208, 0.162) 0.087 (−0.107, 0.281) 0.039 (−0.092, 0.170) 0.56
Age 0.167 (−0.019, 0.353) 0.214 ( 0.021, 0.407) 0.183 ( 0.053, 0.313) 0.0059
Age, sex 0.183 (−0.005, 0.371) 0.242 ( 0.046, 0.439) 0.201 ( 0.069, 0.333) 0.0028
Age, sex, leukocyte distribution (LD) 0.250 ( 0.047, 0.453) 0.274 ( 0.068, 0.481) 0.255 ( 0.115, 0.396) 0.0004
Age, sex, LD, smoking 0.243 (0.038, 0.448) 0.282 (0.074, 0.491) 0.256 (0.113, 0.398) 0.0004
Age, sex, LD, alcohol 0.289 (0.080, 0.497) 0.280 (0.070, 0.490) 0.277 (0.133, 0.421) 0.0002
Age, sex, LD, history of cancer 0.234 (0.030, 0.437) 0.275 (0.067, 0.484) 0.250 (0.108, 0.391) 0.0006
Age, sex, LD, interaction (age accel. with sex)
Estimate in females 0.304 ( 0.036, 0.572) 0.246 (−0.026, 0.519) 0.269 (0.082, 0.455) 0.0048
Estimate in males 0.190 (−0.089, 0.469) 0.307 ( 0.013, 0.601) 0.241 (0.046, 0.436) 0.016
Shown is the estimated change (95 % confidence interval) in FI (expressed in %) per year of age acceleration. All models are adjusted for the methylation array
batch using a random effect
a p values refer to t distribution tests of the estimates obtained by multiple imputation in the overall model
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In this study of more than 1800 community-dwelling
adults, there was evidence for an independent associ-
ation of epigenetic age acceleration with frailty as mea-
sured by a deficit accumulation-based approach.
Quantitatively, the observed association translated into
round about half an additional deficit per 6 years—i.e.,
roughly 1.2 standard deviations—of age acceleration.
Relative telomere length, on the other hand, was not sig-
nificantly associated with age acceleration. These find-
ings suggest that DNAm age acceleration might be
correlated with clinically relevant aging-related pheno-
types, in particular frailty, due to pathways unrelated to
genomic age as assessed by TL.
Age acceleration is associated with a comprehensive
frailty measure
The potential relationship between epigenetic age acceler-
ation and frailty-related phenotypes apparently has been
investigated only in one previous study: in an analysis of
the Lothian Birth Cohort 1936 (LBC1936), significant cor-
relation coefficients ranging from −0.05 to −0.07 were
found between DNAm age acceleration and cognitive
functioning, grip strength, or lung function [10].Table 4 Linear regression models predicting frailty from relative telo
age acceleration
Stratum of age acceleration Dataset 1
Tertile 1 (below −1.85 years) 0.132 (−1.253, 1.517)
Tertile 2 (−1.85 to <2.43 years) −0.982 (−2.635, 0.672)
Tertile 3 (≥2.43 years) 0.960 (−0.763, 2.682)
Shown is the estimated change (95 % confidence interval) of the frailty index (expr
leukocyte distribution, and random effects of telomere and methylation array batch
ap values refer to t distribution tests of the estimates obtained by multiple imputatiGiven that the LBC1936 participants were rather
strictly 70 years of age when assessed for the study of
age acceleration, the present findings extend the prior
evidence from the old to middle-aged-old age group, as
they were based on study participants aged 50 to
75 years. Moreover, whereas age acceleration was suc-
cessfully analyzed with respect to three individual
healthy aging-related characteristics in LBC1936, the
current work employed the frailty index, a more multi-
dimensional approach that combines parameters of mul-
tiple physiological systems and functional capacities [4].
This very robust frailty measure features strong replic-
ability and validity across populations and datasets [13],
fostering the relevance of the present findings and sup-
porting a wide applicability to frailty-related research
questions including study populations that may lack in-
formation on one frailty item or another.
Additional explorations of the association of DNAm age
acceleration with subcomponents of our frailty index,
which had been suggested by a reviewer, yielded intriguing
additional insights: using z-transformed variables in order
to obtain comparable association estimates, we found
DNAm age acceleration to be associated with the
1-item self-rated general health subcomponentmere length (RTL) within tertiles of difference-based methylation
Dataset 2 Overall pa
−0.809 (−3.548, 1.930) −0.106 (−1.274, 1.063) 0.86
−0.404 (−2.266, 1.459) −0.506 (−1.689, 0.678) 0.40
−0.135 (−1.881, 1.611) 0.338 (−0.829, 1.504) 0.57
essed in %) per standard deviation of RTL. All models adjusted for age, sex,
on in the overall model
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disease history subcomponent (0.015, p = 0.0014), and
the 16-item activities of daily living subcomponent
(0.015, p = 0.0019), but not with the 6-item symptoms
subcomponent (0.009, p = 0.061), based on the overall
model adjusted for age, sex, and leukocyte distribu-
tion. The first three association estimates were rather
close to the corresponding value of 0.017 pertaining
to the z-standardized full frailty index. These findings
generally support the robustness of the association of
epigenetic age acceleration with frailty across diverse
domains, whereas the null finding for the symptoms
subcomponent might reflect its substantial inherent
subjectiveness.
Epigenetic processes have been termed an “attractive
candidate” for explaining frailty differences, and methy-
lation levels of some promoter CpG islands are associ-
ated with frailty [14]. Findings for global DNA
methylation and frailty are somewhat inconsistent,
though this might be due to methodological differences
[7, 14]. Major hypotheses advanced in this context in-
clude that the activation of genes involved in a response
to frailty leads to a hypomethylation of respective regula-
tory genomic regions or that deficits in methylation
maintenance lead to a dysregulation of gene expression
and the development of frailty [7]. Intriguingly, the
LBC1936 study found epigenetic age acceleration but
not individual CpG methylation levels to be associated
with their fitness measures [10], suggesting that an “ac-
celerated” epigenetic aging may be more closely corre-
lated to clinically relevant frailty phenotypes than any
individual CpG. However, it ultimately remains unclear
how the interplay of environmental factors and stochas-
tic processes leads to the manifestation of a consistent
(and possibly mechanistically relevant) epigenetic clock
at specific loci in contrast to an overall inconsistent (and
purely correlational) epigenetic drift [15].
Age acceleration and telomere length are not correlated
In the absence of previous pertinent publications, the
analysis of DNAm age acceleration with TL was moti-
vated by the hypothesis that accelerated epigenetic aging
could plausibly be associated also with cellular senes-
cence. The ESTHER study provided no evidence for
such an association. It was furthermore hypothesized
that differences in DNAm age acceleration might be re-
sponsible for the inconclusive prior reports about an as-
sociation of TL with frailty-related phenotypes [8, 9, 12].
However, no association of TL with frailty was found in
the ESTHER cohort, regardless of the level of DNAm
age acceleration.
A limited number of studies have investigated DNA
methylation in association with telomere length. Global
hypomethylation has been suggested to be associatedwith decreasing TL [16], and several individual CpGs are
correlated with TL independent of chronological age
[17]. Age-related differences in the methylation of subte-
lomeric regions further support a close link of epigenet-
ics and cellular senescence [18]. The absence of an
association of TL with epigenetic age acceleration, how-
ever, seems to be in line with evidence suggesting that
DNAm age does not reflect mitotic age [2], which is a
major determinant of age-dependent telomere shorten-
ing [19].
Limitations and strengths
Given the observational, cross-sectional design of the
present study, our findings should not be interpreted as
reflecting causality. Future studies should consider re-
peated measurements of methylation/age acceleration as
well as telomere length and frailty in order to approach
this issue. Methylation analyses were done on whole-
blood DNA, which constitutes a mixture of cells present
in the peripheral circulation. Although methylation pat-
terns are known to vary between tissues, DNAm age as
used in the present study’s main analyses features only a
low correlation with cell types, presumably because it
has been consciously designed as a multi-tissue predictor
based on rather diverse learning data sets [2, 11]. Differ-
ential blood counts were not available in the present
study, but our main models were adjusted for leukocyte
subtype distributions estimated by the Houseman
method, and this had only a minor impact on the re-
sults. Contrasting the aforementioned limitations, the
large size and representative nature of the study sam-
ple, as well as the use of a thoroughly constructed
multi-dimensional frailty measure, are major strengths
of the present work, which featured an altogether
exceptional combination of data on methylation,
telomeres, and frailty.
Towards a better understanding of the human clocks
Knowledge on the interplay of genomic, epigenetic, and
bioclinical aging phenomena remains surprisingly vague.
Even though telomere length has been suggested to have
some effects on phenotype development, current evi-
dence altogether seems to emphasize its role as a rather
innocent bystander of aging and an indicator of lifetime
exposures [19]. Aging-associated CpG sites also are not
generally related to known mechanisms of aging [20],
and it has been described as one of the chief challenges
in this field “to identify the most important genes and
pathways for which altered methylation patterns contrib-
ute to age-related functional decline” [21]. Our study
contributes to an increasing body of literature that sug-
gests that the epigenetic clock relates to a molecular
process that might play a causative role in biological
aging, as exemplified by recent reports showing that
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mortality [22] and is increased in Down syndrome,
which is a segmental progeria [23]. However, the mech-
anistically causal nature of any altered DNA methylation
patterns—including epigenetic age acceleration—for
aging-related phenotypes at present remains speculative.
The most promising way to address this issue may be
genomewide association studies of frailty-associated dif-
ferential CpG methylation and DNAm acceleration,
which could yield instrumental variables for use in so-
called Mendelian randomization studies, an analytical
approach specifically designed for studying causality in
observational settings [24].
Conclusions
Confirming speculations by Horvath, the present find-
ings suggest that epigenetic aging contains information
complementary to that of the telomere clock [2]. The re-
sults on epigenetic age acceleration being associated
with a multi-dimensional frailty phenotype appear prom-
ising, but innovative approaches like Mendelian
randomization will be needed to elucidate the causal
relevance of such patterns linking epigenetic, genomic,
and clinical correlates of age.
Methods
Study design and study population
The present study was based on the ESTHER epidemio-
logical cohort study, which is an observational study of
the elderly general population of Saarland, a federal state
of Germany [25]. In brief, almost 10,000 participants
aged 50 to 75 years were recruited by their general prac-
titioner when presenting for routine health checkups
from June 2000 to December 2002. This cohort is repre-
sentative for this age segment of the community-
dwelling general population of Saarland [25].
In brief, the baseline assessment forming the basis of
the present investigation consisted of obtaining the data
collected as part of the health checkup, drawing a blood
sample that was mailed to the study center and stored at
−80 °C until analysis, and completing a detailed stan-
dardized questionnaire on socio-demographics, lifestyle
factors, and medical history.
For the present study, only subjects with data available
on epigenetic age, telomere length, and frailty (see
below) were considered, and the availability of DNA
methylation data was the principal limiting factor in this
regard. DNA methylation measurements allowing the
calculation of epigenetic age had been obtained from
two subsamples of the source study: substudy 1 included
1000 consecutively recruited ESTHER participants with
sufficient baseline DNA available; substudy 2 included
all ESTHER participants deceased until year 8 follow-up
and with sufficient DNA available (n = 406 afterdiscounting 196 individuals already included in substudy
1), plus 458 additional subjects randomly selected from
ESTHER participants with sufficient DNA available and
not included in substudy 1 or the deceased group. After
discounting subjects with missing data on telomere
length, a total of 1820 participants could be included in
the present analysis (969 (97 %) of substudy 1; 851
(98 %) of substudy 2).
Ethics, consent, and permissions
Inclusion in the ESTHER study, which complies with
the Declaration of Helsinki, was conditional upon writ-
ten informed consent. The study protocol and proce-
dures were approved by the ethics committees of both
the Medical Faculty of the University of Heidelberg and
of the Medical Association of Saarland.
Epigenetic age and age acceleration
The DNAm age was calculated based on a predictor de-
veloped in a large study of genomewide methylation
array datasets [2] using the R tutorial of the pertinent
publication. Note that DNAm age was calculated using
the exact predictor developed by Horvath [2] without
re-training the model on the present data. In brief,
DNAm age is calculated from methylation levels at 353
CpG sites. This measure has been suggested to reflect
the “cumulative work done by an epigenetic mainten-
ance system” and is highly correlated with chronological
age [2]. The so-called difference-based DNAm age accel-
eration can be calculated by subtracting the chrono-
logical age from the predicted DNAm age [2].
Methylation levels were determined using the Infinium
HumanMethylation450 BeadChip (Illumina, San Diego,
CA) at the Genomics and Proteomics Core Facility of
the German Cancer Research Center, Heidelberg,
Germany. Methodological details have been published
previously [1].
Telomere length
As a measure of relative telomere length (TL), the telo-
mere repeat copy number to the number of single-copy
gene ratio (T/S ratio) was determined using a quantitative
PCR approach [26]. The assay used the single-copy gene
36B4 for reference, and the PCR was done on a Lightcy-
cler® 480 (Roche Diagnostics, Mannheim, Germany).
Further details on the TL measurements, including quality
control and assay validation, have been published
elsewhere [27].
Frailty index
As a measure of frailty, a FI based on the accumulation
of deficits was calculated as previously described [3]. In
brief, the FI is defined as the proportion of deficits
present, where the exact deficits considered in the
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[13]. In the ESTHER study population, the FI was con-
structed following standard recommendations [13] and
ultimately based on 34 deficits (i.e., one additional deficit
increases this FI by 0.029 or 2.9 % points), including
poor self-rated general health, history of various diseases
(11 items: myocardial infarction, angina pectoris, heart
failure, stroke, hypertension, hyperlipidemia, diabetes,
cataract, glaucoma, gout, cancer), difficulties in the activ-
ities of daily living (16 items: “vigorous activities,”
“climbing several flights of stairs,” “climbing one flight
of stairs,” “walking more than one mile,” “walking several
blocks,” “walking one block,” “moderate activities, such
as moving a table, pushing a vacuum cleaner, bowling,
or playing golf,” “lifting or carrying groceries,” “bathing
or dressing yourself,” “bending, kneeling or stooping,”
“limits in normal work or activities due to pain,” “ac-
complished less work or activities due to impaired phys-
ical health,” “limits in type of work or activities due to
impaired physical health,” “difficulties chewing hard
food,” “difficulties chewing meat,” “short-term memory
loss”), and various symptoms (six items: under-/over-
weight, pyrosis, shiver, insomnia, costiveness, aconur-
esis). Missing values in the variables needed for the
frailty index calculation were dealt with by multiple
imputation [3], and models including FI in the present
analysis were based on 20 imputations combined by the
SAS procedure MIANALYZE.
Statistical methods
The study population was first described with respect to
the main analysis variables, major participant characteris-
tics, and important covariables (smoking behavior (never,
former, current), alcohol consumption (none, 1–19
(women) or 1–39 (men) g/d, 20+ (women) and 40+ (men)
g/d), history of cancer). Histograms were used to explore
the distribution of DNAm age acceleration, TL, and FI.
Subsequently, linear regression models predicting TL or
FI from DNAm age acceleration were fitted with increas-
ing adjustment sets: no covariables; age; age, sex; age, sex,
and leukocyte subtype distributions (LD) estimated ac-
cording to the Houseman method [28] (main model).
Random effects were included in the models to account
for methylation array and telomere assay batch effects.
Subsequently, the sensitivity of the main model results to
additional adjustment for smoking, alcohol or history of
cancer was studied. In addition, sex-specific estimates
were examined. Finally, the potential interaction of telo-
mere length and epigenetic age acceleration on frailty was
examined by fitting linear regression models predicting FI
from TL within tertiles of DNAm age acceleration. For
this purpose, linear models including continuous TL,
DNAm age acceleration tertiles, and the interaction of
these two variables were analyzed; the categorization andway of presentation as nested effects was chosen for the
ease of interpretability.
The regression models were generally fit first to dataset
1 and dataset 2 separately and then to the combined data-
set. Additional sensitivity analyses included the use of in-
verse sampling probability weights (i.e., adjustment for the
oversampling of deceased subjects due to the case-cohort
design of substudy 2) in the combined dataset models.
Statistical significance was defined as p < 0.05. All data
analyses were done using SAS 9.3.
Availability of data and materials
Data protection standards and assurances made as part
of the informed consent procedure of ESTHER preclude
the publication of the source data in publicly available
repositories. However, individual data access may be
granted within a framework of scientific cooperation.
Additional file
Additional file 1: Figure S1. Distribution of main analysis variables.
Shown are the histograms (overlay: fitted Normal distribution) of
difference-based DNAm age acceleration (A, B), relative telomere length
(C, D), and frailty index (E, F; based on one instance of the multiple
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